The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...

SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...